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The human immunodeficiency virus type 1 (HIV-1) Nef protein has several independent functions that might
contribute to efficient viral replication in vivo. Since HIV-1 adapts rapidly to its host environment, we
investigated if different Nef properties are associated with disease progression. Functional analysis revealed
that nef alleles obtained during late stages of infection did not efficiently downmodulate class I major
histocompatibility complex but were highly active in the stimulation of viral replication. In comparison,
functional activity in downregulation of CD4 and enhancement of HIV-1 infectivity were maintained or
enhanced after AIDS progression. Our results demonstrate that various Nef activities are modulated during
the course of HIV-1 infection to maintain high viral loads at different stages of disease progression. These
findings suggest that all in vitro Nef functions investigated contribute to AIDS pathogenesis and indicate that
nef variants with increased pathogenicity emerge in a significant number of HIV-1-infected individuals.
One factor that enables human immunodeficiency virus
(HIV-1) to replicate efficiently and continuously despite a
strong host antiviral immune response is the Nef protein. First,
it has been shown that simian immunodeficiency virus (SIV)
carrying a deletion in nef replicates inefficiently and does not
cause disease in adult rhesus macaques (21). Subsequently,
several long-term survivors of HIV-1 infection were identified,
in whom only nef-deleted proviruses could be detected (10, 26).
These individuals had low viral loads and unusually slow dis-
ease progression. Finally, the HIV-1 nef gene enhances the
pathogenicity of SIV (1, 23).
A number of in vitro Nef activities which might contribute to
the maintenance of high viral load and disease progression
have been described (reviewed in references 9 and 12). Nef
downregulates the cell surface expression of CD4, the primary
receptor of HIV and SIV (14). A smaller number of CD4
molecules at the cell surface could promote the release of
progeny virions, result in enhanced envelope incorporation
into viral particles, prevent superinfection, alter T-cell receptor
signaling, and impair immune functions of CD41 helper T cells
(2, 27, 34, 37). Nef also downregulates class I major histocom-
patibility complex (MHC) cell surface expression (35). This
activity allows infected cells to resist killing by cytotoxic T
lymphocytes (CTL) (6). Interestingly, class I haplotypes that
protect the cells against lysis by natural killer cells are not
affected by Nef (5). Selective downregulation of class I MHC
proteins might contribute to immune evasion by HIV-1. In
addition to inducing class I MHC and CD4 endocytosis, Nef
increases the infectivity of viral particles derived from CD4-
negative producer cells (28, 31) and enhances viral replication
in peripheral blood mononuclear cells (PBMC) (4, 28, 31, 38).
All these Nef functions could potentially contribute to effi-
cient viral replication and disease induction in vivo. Their phys-
iologic relevance has been questioned, however, particularly
since some effects were observed under artificial conditions or
require very high Nef expression levels and since other HIV-1
proteins also downregulate CD4 (8, 42). Therefore, it is not
entirely clear why Nef plays a key role in HIV-1 replication and
progression to AIDS.
An interesting aspect of Nef function is that most in vitro
activities seem to involve different interactions with the cellular
signal transduction and endocytic machinery and are function-
ally separable (19, 28, 29, 32, 39). Several conserved activities
of Nef are mediated by different regions of the protein, sug-
gesting that they are independently selected in vivo. Since
HIV-1 adapts very rapidly to its host environment (11), we
speculated that different Nef functions may be selected for at
different stages of infection.
To challenge this hypothesis, we investigated if the relative
functional activities of Nef change during the course of HIV-1
infection. We found that nef alleles derived from asymptomatic
individuals efficiently downregulated the cell surface expres-
sion of class I MHC. In contrast, nef alleles obtained after
AIDS progression were impaired in class I MHC downmodu-
lation but highly active in the stimulation of HIV-1 replication.
Functional activity in CD4 downregulation and enhancement
of infectivity was maintained or enhanced during the late
stages of infection. In conclusion, in immunocompetent hosts,
Nef properties are selected that allow the virus to efficiently
escape the CTL response, whereas in AIDS patients the selec-
tive forces drive Nef variations that enhance viral spread in a
more direct manner. Importantly, our results also suggest that
all four in vitro Nef functions analyzed contribute to viral
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spread in vivo and that the pathogenic properties of HIV-1
change during progression to AIDS.
MATERIALS AND METHODS
Plasmid construction. nef alleles predicting the five consensus Nef amino acid
sequences were constructed using a combination of splice-overlap extension
PCR mutagenesis and standard DNA techniques. The consensus nef alleles were
generated based on the previous analysis of nef sequences derived from 91
HIV-1-infected individuals at different stages of disease (24). nef alleles were
cloned into a full-length HIV-1 NL4-3 proviral clone essentially as described
previously (3). Briefly, the env region of NL4-3 was amplified using primer pSi1
(59-TAGTGAACGGATCCTTAGC-39; 8572 to 8590) containing a BamHI re-
striction site (bold) and pSi3 (59-TGACCACTTGCCACCCAT-39; 8902 to
8919). The five consensus nef genes were amplified using primer pSi4 (59-ATG
GGTGGCAAGTGGTCA-39; 8902 to 8919) and pSi2 (59-TTCTTGTAGTACT
CCGGATGC-39; 9495 to 9515) containing an MroI site (bold). Numbers refer to
the primer positions in the HIV-1 NL4-3 genome. The left- and right-half PCR
products were gel purified, mixed at equimolar amounts, and subjected to a
second PCR with primers pSi1 and pSi2. The PCR products were purified and
inserted into a vector containing the env-nef-long terminal repeat region of
NL4-3 by using the BamHI and MroI sites in the env and nef genes. Subsequently,
the env-nef-long terminal repeat region was inserted into a modified pBR322
vector containing the full-length HIV-1 NL4-3 proviral DNA by using the unique
BamHI and XbaI sites in the NL4-3 env and the vector sequences flanking the 39
end of the provirus. For Nef expression in Jurkat T cells, the nef sequences were
cloned into a bicistronic cytomegalovirus-based pCG expression vector, as de-
scribed previously (29). All PCR-derived inserts were completely sequenced to
confirm that they represented the desired nef gene sequences. Primary nef alleles
were amplified by PCR as described previously (24). Amplification products were
gel purified and used for a final round of amplification with primers that allowed
cloning into the pCG expression vector and insertion into a nef-deleted NL4-3
clone (3), respectively. Cloning was performed essentially as described above,
except that the patient-specific nef sequence variations were introduced into the
primers used for PCR amplification. The digested PCR fragments were cloned as
a pool, and the transformation and cloning efficiencies were determined essen-
tially as described previously (23). Individual participants with earlier designa-
tions in the literature are as follows: LTNP4, HP (16, 17, 30); SP7, MB (24, 30);
and P2, FA (24, 30).
Study populations. Sequential samples were obtained from six individuals in
the cohort monitored at the New England Hemophilia Center at the UMass/
Memorial Health Care System, Worcester, Mass., since 1983. These individuals
were selected by a CD41 T-cell profile that showed an early rapid decline or a
clear time point of inflection. They were further selected by the availability of
samples from time points when CD41 T-cell counts were normal and after
declining to ,100/ml. With the exception of P10 (1986), all individuals tested
HIV positive in 1983. Currently, SP8 and P9 are alive with AIDS and the
remaining individuals have died. All participants have given informed consent for
these studies, with the approval of the institutional review board on the conduct
of research on human subjects at the UMass Medical School.
Transfections and flow-cytometric analysis. Transfection of Jurkat T cells was
usually performed by electroporation as previously described (15, 19, 29). For the
analysis of pooled primary nef alleles, DMRIE-C reagent (Gibco-BRL,
Karlsruhe, Germany) was used as specified by the manufacturer. Flow cytometry
analysis of CD4, class I MHC, and green fluorescent protein (GFP) reporter
molecules in cells transfected with a bicistronic vector coexpressing Nef and GFP
was measured as described previously (15, 29). The level of CD4 or class I MHC
expression (red fluorescence) was measured from aliquots of the same transfec-
tion mixture as a function of GFP green fluorescence. For the quantitation of
Nef-mediated CD4 or class I MHC downregulation, the mean channel numbers
of red fluorescence were determined for cells expressing no (N), low (L), me-
dium (M), or high (H) levels of GFP. The numbers obtained for cells transfected
with vector expressing GFP only were divided by the corresponding numbers
obtained for cells coexpressing Nef and GFP, to calculate the values for x-fold
downmodulation.
Cell culture, infectivity, and viral replication assays. Virus stocks were gen-
erated by transient transfection of 293T cells, and replication and infectivity
assays were performed essentially as described previously (3). The effect of Nef
on viral replication in human PBMC culture was to some extent dependent on
the blood donor. Therefore, infections with the wild-type HIV-1 NL4-3 isolate
and with a mutant containing a deletion of 260 -bp in the nef- unique region (3)
were always performed in parallel with the analysis of primary or consensus nef
alleles. Furthermore, the replicative capacity of all NL4-3 nef variants was de-
termined in at least three independent experiments using different virus stocks
and PBMC derived from different donors.
Statistical analysis. Statistical analysis was performed using the InStat pro-
gram version 3.0 (GraphPad Software, San Diego, Calif.).
RESULTS
Activity of progressor and nonprogressor consensus nef al-
leles. We have previously shown that certain amino acid vari-
ations in HIV-1 Nef are associated with different stages of
disease (24). To assess the relevance of these variations for Nef
function, we generated five nef alleles: the consensus alleles
obtained from a large number of nonprogressors (NPcon) and
from immunodeficient individuals (Pcon), which differ at only
four amino acid positions (T15A, N51T, L170Q, and E182M);
nef alleles that contained additional changes that were more
commonly observed in nonprogressors (Y102H) (NPex), or in
progressors (K39R, N157T, S163C, and S169N) (Pex); and an
additional substitution (V11P), which creates an N-terminal
PxxP sequence (PexP). The predicted Nef amino acid se-
quences differed only in the specific changes shown in Fig. 1a.
An overview on the nef alleles analyzed in this study is given in
Table 1.
To investigate their effect on CD4 and class I MHC cell
surface expression, the five consensus nef alleles were cloned in
a bicistronic expression vector containing nef followed by GFP
under the control of an internal ribosome entry site IRES
element (29). Thus, the Nef proteins are expressed from a
single bicistronic mRNA in a constant stoichiometry with the
GFP reporter molecule. All five consensus nef alleles and the
control NA7-Nef (15, 19) efficiently downregulated CD4 and
class I MHC (Fig. 1b). The Pex and PexP nef alleles, however,
showed two- to three-fold-higher activities in CD4 downregu-
lation (L, 26.7 6 4.4; M, 54 6 9.6; H, 56 6 17.4 [n 5 6]) than
did the NPcon and NPex alleles (L, 9.4 6 2.1; M, 26.1 6 3.1;
H, 19.1 6 3.7 [n 5 6]). The values give x-fold downregulation
for low, medium, and high GFP coexpression levels, respec-
tively. In contrast, the NPcon and NPex nef alleles revealed
two- to three-fold-higher maximum activity in class I MHC
downregulation (Fig. 1b). These functional differences be-
tween the Pex and NP nef alleles were consistently observed in
at least three experiments and were highly significant (P ,
0.002). The results were not biased by different transfection
efficiencies, because both CD4 and class I MHC were mea-
sured simultaneously from the same transfection. To assess
their effect on virion infectivity and replication, the consensus
nef alleles were cloned into the proviral HIV-1 NL4-3 genome.
As shown in Fig. 1c, all nef alleles increased virion infectivity.
Notably, the Pex and PexP alleles were about two fold more
active than the Pcon, NPcon, NPex, NL4-3, and NA7 nef al-
leles. Similarly, all nef alleles stimulated viral replication in
PBMC (Fig. 1d). The three progressor nef alleles showed con-
sistently higher activity, however, than the two NP nef alleles.
To confirm this result, we coinfected PBMC with these NL4-3
nef variants and passaged the virus four times in PBMC of
different donors. Sequence analysis revealed that the progres-
sor variants outgrew the nonprogressor nef variants in primary
PBMC cultures (data not shown).
These results show that amino acid variations in Nef more
frequently observed among nonprogressors were associated
with high activity in downmodulation of class I MHC, a func-
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tion which might allow the virus to escape antiviral CTL re-
sponses. In comparison, Nef proteins containing features com-
monly observed in immunodeficient patients were more active
in downregulation of CD4 and enhancement of HIV-1 repli-
cation and infectivity.
Loss of efficient Nef-mediated class I MHC downregulation
after progression to AIDS. Next, we investigated if these dif-
ferences in aspects of Nef function, observed using consensus
nef alleles, are also obtained with primary nef genes. Previous
analysis of sequential samples derived from two patients, P2
and SP7, revealed that several variations in Nef, which were
more commonly observed in AIDS patients, were detected
only during or after progression to immunodeficiency (24). To
assess the effect of these alterations on Nef function, we ana-
lyzed two nef alleles derived from each patient. One was ob-
tained early in infection (SP7-88 and P2-87), and the second
was obtained during (SP7-91) or after (P2-93) progression to
AIDS (Table 1). Notably, both nef alleles predicted amino acid
sequences that were identical to .50% of the sequences am-
plified from the respective PBMC samples and thus were rep-
resentative for these time points.
As shown in Fig. 2a the nef alleles obtained after the onset
of immunodeficiency, P2-93 and SP7-91, were about two- to
three-fold more active in downregulation of CD4 compared to
the P2-87 and SP7-88 alleles. In comparison, the P2-87 and
SP7-88 nef alleles, obtained during the asymptomatic stage of
infection, downmodulated class I MHC with about 10- to 20-
fold higher efficiency than did the late nef alleles (Fig. 2a). The
P2-93 and SP7-91 nef alleles were slightly more active than the
P2-87 and SP7-88 alleles in the enhancement of virion infec-
tivity (Fig. 2b). The P2 nef alleles stimulated viral replication in
PBMC more efficiently than the SP7 nef alleles did (Fig. 2c).
For both patients, however, the late nef alleles were consis-
tently more active than the nef genes amplified from the early
samples (Fig. 2c). Coinfection experiments confirmed that the
P2-93 variant outgrew the P2-87 variant (data not shown).
The functional analysis of nef alleles derived from these two
individuals with progressive disease extended the observations
made with the consensus nef alleles and revealed a dramatic
loss of Nef-mediated class I MHC downregulation after pro-
gression to AIDS. In contrast, other Nef functions that are
probably associated with increased HIV-1 virulence (CD4
downmodulation, and enhancement of replication and infec-
tivity) were increased during later stages of infection.
Nef alleles from a long-term nonprogressor are impaired in
the stimulation of viral replication and CD4 downregulation.
The results obtained with the progressor samples suggested
that Nef functions that allow the virus to evade the immune
system are diminished after the onset of immunodeficiency
whereas other activities are increased. In the next set of exper-
iments we investigated which Nef functions are preserved in
nonprogressive HIV-1 infection.
The nef alleles were derived from LTNP4, who shows no
signs of immunodeficiency and has an undetectable viral RNA
load despite more than 17 years of documented HIV-1 infec-
tion (16, 17). It has been previous shown that this long-term
nonprogressor contains a high percentage of defective nef al-
leles (30): 32% of the reading frames were lacking the initia-
tion codon or contained premature stop codons, and 37%
predicted mutations of A56D and E174K that disrupted CD4
downregulation. The remaining 31% were functional in CD4
downregulation, but the activity was relatively low. Notably,
these functional nef alleles, obtained over a 12-year period,
were identical to each other and to an ancestral LTNP4 nef
sequence, suggesting that they represent archival viral DNA
rather than actively replicating virus (30).
To investigate if LTNP4 nef alleles were selectively impaired
in CD4 downmodulation or also nonfunctional in other in vitro
FIG. 1. Activity of nonprogressor and progressor consensus nef
alleles. (a) Amino acid variations between NP and P consensus Nef
sequences. Numbers refer to the corresponding position in the NL4-3
Nef amino acid sequence. (b) Flow cytometric analysis (upper panel)
and quantitative effect of the indicated nef alleles on CD4 and class I
MHC cell surface expression (lower panel). Flow cytometric analysis
was performed, and CD4 and class I MHC expression was determined,
as described in Materials and Methods. Ranges for green fluorescence
on cells defined as expressing no (N), low (L), medium (M), or high
(H) levels of GFP are indicated. (c) MAGI cells were infected in
triplicate with aliquots of three different 293T cell-derived virus stocks
containing 125 ng of p24 core antigen. Infectivity is shown relative to
HIV-1 NL4-3 wild type. Error bars correspond to standard deviation.
(d) Replication of the NL4-3 variants containing the indicated nef
alleles (for symbols, see panel a) in PBMC. Cells were infected imme-
diately after infection and stimulated with phytohemagglutinin 3 days
later. All results were confirmed in at least three independent exper-
iments. PSL, photostimulated light emission.
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assays, we analyzed primary alleles and several recombinants
with the functional NA7 nef allele (30) (Fig. 3a). The LTNP4-
91B1 and LTNP4-91(A,E) nef alleles were representative for
the majority of intact nef open reading frames amplified from
LTNP4 over a 12-year period of PBMC sampling. In agree-
ment with the previous study, the A56D and E174K substitu-
tions resulted in inefficient CD4 downmodulation (Fig. 3b and
c). However, even the LTNP4-91(A,E) Nef showed about a
10-fold reduced activity compared to the NA7 Nef (Fig. 3c). In
contrast to the highly divergent effects of the different nef
recombinants on CD4 cell surface expression, all forms effi-
ciently downregulated class I MHC (Fig. 3d) and enhanced
virion infectivity (Fig. 3e). The effects of these nef alleles on
viral replication in PBMC were variable, depending on the
donor. In two experiments, NL4-3 containing the LTNP4-A-
NA7 and LTNP4-91(A,E) nef alleles replicated as efficiently as
the NL4-3 and NA7 controls (an example is shown in Fig. 3f);
and in three other infections, they showed an intermediate
phenotype. Overall, the results from five independent experi-
ments revealed that nef alleles that downregulated CD4 were
also active in the stimulation of viral replication whereas the
LTNP4-91B1 and LTNP4-NA7 Nef proteins were impaired in
both assays. These data are consistent with reports that down-
regulation of CD4 and the enhancement of viral replication
involve similar molecular interactions (27, 34).
These results demonstrate that nef alleles derived from
LTNP4 showed the opposite phenotype from nef alleles de-
rived from AIDS patients: efficient class I MHC downregula-
tion but inefficient downmodulation of CD4 and stimulation of
viral replication. In agreement with a previous study (3), these
results suggest that Nef functions which allow the virus to
escape immune surveillance are maintained in nonprogressive
HIV-1 infection whereas other Nef activities that probably
contribute to the full pathogenic potential of HIV-1 might be
impaired.
Functional activity of sequential nef alleles from progressors
with HIV-1 infection. The consensus Nef sequences were de-
rived from a large number of patients (24), and representative
nef alleles derived from patients P2, SP7, and LTNP4 were
selected for functional analysis. Nonetheless, the number of
alleles analyzed was limited, and the possibility that the results
did not accurately reflect the course of primary HIV-1 infec-
tion could not be dismissed. Therefore, additional experiments
with nef alleles derived from sequential patient samples were
performed.
nef alleles derived from PBMC samples obtained from six in-
dividuals with progressive HIV-1 disease for between 6 and 14
years were analyzed. All study subjects showed a dramatic de-
crease in the number of CD41 T cells and progressed to AIDS
during the investigation period (Table 2). The amplified PCR
products were cloned directly into the bicistronic pCG-Nef-IRES-
GFP vector or used to introduce nef genes into the nef-deleted
HIV-1 NL4-3 molecular clone by splice overlap extension-PCR.
A complex mixture of primary nef alleles was cloned as a pool to
ensure that the nef genes analyzed were representative of each
patient and time point. Control experiments indicated that $95%
of the expression vector and the proviral construct contained an
insert of the expected size and that each plasmid preparation
represented at least 250 independent transformants. Western blot
analysis revealed that all plasmid populations resulted in efficient
Nef protein expression (data not shown). A total of 80 colonies
were randomly picked from the transformation of both the pro-
viral (44 colonies) and the pCG-Nef-IRES-GFP (36 colonies)
constructs. Agarose gel analysis confirmed that 43 (98%) and 34
(94%), respectively, of the clones contained an insert of the ex-
pected size, and sequence analysis showed that all positive clones
contained nef alleles that were specific for the respective patient
(data not shown).
As indicated in Table 2, primary nef alleles derived from all 18
samples downmodulated the cell surface expression of CD4. In
three of the six patients (SP8, P5, and P7) the efficiencies re-
mained relatively constant over the course of infection. For the
remaining individuals, P8, P9, and P10, a significantly (P , 0.01)
increased activity was observed after progression to AIDS. At
medium expression levels, nef alleles obtained during late stages
of infection were about two-fold more active than nef alleles
obtained during the asymptomatic stage (Table 2). The functional
differences in class I MHC downmodulation were more dramatic.
nef alleles amplified early in infection from five of the six study
subjects showed activities that were comparable to that of the
TABLE 1. Overview of the selected HIV-1 Nef variants analyzed
Group nef allelea Remarks




PexP Pex plus additional N-terminal proline
Group 2 (progressor nef alleles) P2-87 Early allele from progressor P2; CD41 cell count, 536/mm3
P2-93 Late nef allele from progressor P2; CD41 cell count, 18/mm3
SP7-88 Early nef allele from progressor SP7; CD41 cell count, 1,264/mm3
SP7-91 Late nef allele from progressor SP7; CD41 cell count, 497/mm3
Group 3 (nonprogressor nef alleles) LTNP4-91B1 Clade 2 nef allele from LTNP4
LTNP4-91(A,E) Clade 3 nef allele from LTNP4
Group 4 (pooled sequential nef alleles) SP8-84 Pooled alleles derived from a PBMC sample drawn in 1984
SP8-87 Pooled alleles derived from a PBMC sample drawn in 1987
SP8-96 Pooled alleles derived from a PBMC sample drawn in 1996
a The consensus Nef sequences and nef alleles derived from patients P2, SP7, and LTNP4 have been described previously (24, 30); the complete list of pooled nef
alleles (group 4) is shown in Table 2.
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strong NA7 control nef allele. Importantly, in all five cases, nef
alleles amplified after AIDS progression showed strongly dimin-
ished activity (P , 0.01). In contrast, nef alleles amplified from P8
always showed low activity in class I MHC downregulation, even
for the sample drawn prior to progression to AIDS (Table 2). The
results obtained for Nef function were consistent with the se-
quencing data, showing that only in P8 no specific sequence vari-
ations in Nef were observed during progression to AIDS (data
not shown). On average, the maximum levels of Nef-mediated
class I MHC downregulation dropped about 10-fold after pro-
gression. To assess the effect on infectivity and replication, virus
stocks were generated by transient transfection of 293T cells with
the NL4-3 proviral clones carrying the primary HIV-1 nef alleles.
Infection of MAGI cells revealed that in four of six patients the
ability of nef to increase virion infectivity remained constant or
increased only slightly throughout the course of infection. nef
alleles amplified from P7 and P9 showed about a three-fold in-
crease in activity after progression to AIDS (P , 0.01). Similar to
the results for infectivity, all inserted nef pools were able to stim-
ulate HIV-1 replication in human PBMC cultures. Notably, nef
alleles amplified from late PBMC samples consistently showed
two- to three-fold-higher activity than did nef alleles amplified
from samples drawn early in infection (Table 2). This increase in
the ability of Nef to stimulate HIV-1 replication in PBMC culture
was highly significant (P , 0.001).
The relative in vitro activities of Nef change during the course
of HIV-1 infection. The relative functional differences observed
between the various consensus Nefs proteins and between pri-
mary nef alleles obtained before and after disease progression are
summarized in Fig. 4. Consensus Nef proteins containing features
that were more frequently found in progressors (Pex and PexP)
showed slightly to moderately higher activity in three in vitro assay
systems, (i) CD4 downregulation, (ii) enhancement of virion in-
fectivity, and (iii) stimulation of HIV-1 replication in PBMC, than
did proteins from NPcon and NPex. The NP nef alleles were
about 2.5-fold more effective, however, in downmodulation of
class I MHC cell surface expression (Fig. 4). Despite these func-
tional differences, all consensus nef alleles were highly active com-
pared to patient-derived nef alleles. The consensus progressor
and nonprogressor nef alleles predicted the predominant amino
acid residue observed in a large number of patient-derived sam-
ples at each position (24). Therefore, they might express opti-
mized Nef proteins.
The observation that functional differences in Nef are selected
during or after AIDS progression was confirmed using primary
patient-derived nef alleles. The functional activities of primary nef
alleles obtained at different stages of infection are indicated in
Fig. 5. nef alleles derived from AIDS patients generally showed
very low activity in class I MHC downmodulation (,100 CD41
cells/ml, 6.7 6 2.1, [n 5 7]; .500 CD41 cells/ml, 63.6 6 46.2, [n 5
11]) (Fig. 5). However, these late nef alleles were frequently more
active than nef alleles derived from asymptomatic individuals with
high CD41 T cell counts in other in vitro assays for Nef function,
particularly in the stimulation of viral replication (,100 CD41
cells/ml, 10.1 6 1.8 [n 5 7]; .500 CD41 cells/ml, 3.9 6 1.4, [n 5
11]) (Fig. 5). The results obtained with these primary nef alleles
confirmed that (i) efficient Nef-mediated class I MHC downregu-
lation is lost after progression to AIDS, (ii) late nef alleles fre-
quently show higher activity in stimulation of viral replication in
PBMC cultures, and (iii) functional activity in downmodulation of
CD4 and enhancement of virion infectivity are usually maintained
and sometimes increased during late stages of infection (Fig. 4
and 5; Table 2).
DISCUSSION
This study demonstrates that nef alleles found during asymp-
tomatic infection are more active in class I MHC downregu-
lation whereas Nef features typically found after progression to
AIDS are associated with higher activity in stimulation of viral
replication and frequently also with more effective downmodu-
lation of CD4 and enhancement of virion infectivity. Our re-
sults indicate a link between Nef function and the immune
status of the infected individual and are in agreement with
recent reports suggesting that Nef performs multiple separable
in vitro activities that might be independently selected for in
vivo (19, 20, 28, 29, 32, 39). Obviously, a selective advantage
FIG. 2. Inefficient Nef-mediated class I MHC downregulation after
disease progression. (a) Flow cytometric analysis and quantitative pre-
sentation of CD4 and class I MHC downregulation by nef alleles
obtained from patients P2 and SP7 prior (87 and 88 samples) and
during or after disease progression (91 and 93 samples). (b and c) Viral
infectivity (b) and enhancement of viral replication by P2 and SP7 nef
alleles (c). Parameters were determined and reproduced in indepen-
dent experiments, as described in the legend to Fig. 1.
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might also result from other factors, e.g., escape from neutral-
izing-antibody and CTL responses or an expanded cell or co-
receptor tropism (11). Therefore, suboptimal HIV-1 Nef vari-
ants might become predominant if the viruses contain
mutations elsewhere in the genome that result in a significant
growth advantage. Nonetheless, our findings suggest that more
virulent Nef variants are selected in a significant number of
infected individuals.
The observed changes in Nef function probably reflect an ad-
aptation of HIV-1 to its host environment (Fig. 6). Presumably,
the selective pressure for efficient Nef-mediated class I MHC
downregulation is high during the asymptomatic phase of infec-
tion, particularly in patients who show effective CTL responses. In
contrast, HIV-1 Nef variants that induce efficient class I MHC
downregulation would have no selective advantage after progres-
sion to AIDS, when the immune system is destroyed, and in rapid
progressors who are unable to mount an efficient antiviral CTL
response. This might explain the low activity of nef alleles derived
from P8, who progressed rapidly to AIDS. The alterations in the
ability of Nef to downmodulate class I MHC at different stages of
disease strongly suggest that this in vitro activity of Nef does play
a role in immune evasion and efficient viral persistence in the
infected host.
Despite the mechanisms developed by HIV-1 to escape the
antiviral immune response, infected cells have a short half-life
and are efficiently eliminated in immunocompetent individuals
(18, 41). Highly aggressive SIV nef variants, which cause strong
T-cell activation, can evolve in immunodeficient macaques (13,
25). However, the mutations in Nef which are associated with
high virulence revert after the onset of the cellular immune
response (36). The functional differences observed in our study
were more subtle. Nonetheless, these observations suggest that
immunodeficiency viruses containing nef alleles that stimulate
viral gene expression and replication have only a moderate a
selective advantage over variants that cause stronger T-cell
activation in immunocompetent hosts. Notably, we have pre-
viously found that nef alleles derived from a long-term survivor
of HIV-1 infection did not stimulate viral replication in pri-
mary PBMC culture (3).
In agreement with the observation that downregulation of CD4
and class I MHC are independent nef functions (15, 39), late nef
alleles were highly active in CD4 downmodulation. In all pro-
gressing individuals investigated, functional activity remained sta-
ble, suggesting that CD4 downregulation plays a role in viral
replication throughout the course of infection. However, some
primary nef alleles obtained after progression to AIDS and the
Pex nef alleles were particularly active. Possibly some conse-
quences of CD4 downmodulation, e.g., prevention of superinfec-
tion and enhancement of virion production, might be more im-
portant for optimal viral spread during late stages of disease,
when a high percentage of CD41 target cells are already infected.
Interestingly, nef alleles derived from two long-term nonprogres-
sors were selectively impaired in CD4 downmodulation (3, 30)
(Fig. 3). CD4 is crucial for helper T-cell signaling, and the lack of
FIG. 3. nef alleles derived from a long-term nonprogressor are selectively impaired in CD4 downmodulation and stimulation of viral replication.
(a) Structure of the chimeric and mutant Nef proteins that were analyzed (30). (b) Effect of the LTNP4-91-B1 nef allele on CD4 and class I MHC
cell surface expression. (c to f) Functional activity of the indicated mutant and chimeric nef alleles in downregulation of CD4 (c), class I MHC
downmodulation (d), enhancement of viral infectivity (e), and stimulation of HIV-1 replication in PBMC (f). Symbols are shown in panel a. For
all four in vitro assay systems for Nef function, similar results were obtained in two to four independent experiments. Error bars shown in panel
e represent standard deviation.
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efficient virus-specific proliferative responses might be of major
importance for progression to AIDS (33). To understand how the
virus can be controlled by the immune system, it will be important
to clarify if nonprogressors frequently harbor HIV variants that
are defective in this aspect of Nef function and are able to main-
tain strong HIV-1-specific T-helper-cell responses.
The enhancement of virion infectivity was preserved among
all nef alleles investigated. Thus, although infection of MAGI
cells represents a relatively artificial system, it might reflect a
Nef activity that plays an important role in vivo. Obviously,
enhancement of virion infectivity should always be advanta-
geous for viral spread. However, the selective pressure might
FIG. 4. Functional differences between nef alleles representing different stages of HIV-1 infection. Functional activity of a consensus nonprogressor
nef allele (NPex), primary alleles obtained during the asymptomatic stage of infection (P2-87 and SP7-88), and the average activities obtained from the
first samples drawn from the six patients in Fig. 4 (Pat E) were assigned a value of unity. The functional activity of other nef alleles is shown relative to
these forms. Values for CD4 (at medium GFP expression levels) and class I MHC (at high GFP expression levels) downregulation were obtained from
three to six independent experiments. Values obtained for the enhancement of viral replication were derived from four to six infections and represent
relative reverse transcriptase activities measured at the peak activity of the NL4-3 wild-type strain, which was observed between 9 and 13 days
postinfection. Infectivity values represent at least nine measurements with three independent virus stocks. Error bars give the standard deviations.
TABLE 2. In vitro activities of pooled nef alleles obtained at different stages of HIV-1 infection





MHC downregulationb CD4 downregulationb
Infectivityc Replicationc
L M H L M H
SP8 1984 616 NDd 2.8 5.2 28.4 2.9 8.7 67.3 10.8 6 1.5 5.0 6 1.7
1987 601 ND 2.7 5.2 28.9 2.8 9.1 75.6 11.2 6 1.2 3.4 6 0.6
1996 39 ND 2.1 2.5 2.2 3.2 9.9 87.4 14.9 6 1.8 10.8 6 2.3
P5 1983 616 11,987 2.4 5.4 45.1 2.1 3.3 45.3 13.2 6 1.4 3.2 6 0.2
1991 121 11,992 2.3 3.6 6.7 2.4 4.0 54.9 9.9 6 0.5 5.7 6 1.8
1995 5 11,994 2.2 3.3 5.3 2.6 5.1 59.5 9.1 6 1.2 11.0 6 3.1
P7 1982 ND ND 2.8 7.4 38.5 2.5 7.5 76.8 8.9 6 1.5 4.5 6 2.4
1985 822 ND 2.5 4.9 24.0 2.9 10.3 78.0 19.6 6 3.9 4.8 6 0.7
1993 7 ND 2.0 2.9 8.7 2.9 8.4 70.3 26.2 6 5.1 7.2 6 2.0
P8 1983 526 11987 2.9 5.0 10.3 2.7 6.5 60.8 7.8 6 1.2 4.0 6 1.0
1987 126 ND 3.0 4.6 9.9 3.3 11.4 78.7 9.1 6 1.5 11.3 6 3.5
1989 12 ND 3.3 4.9 9.0 3.2 14.6 89.3 11.1 6 0.5 9.0 6 2.3
P9 1984 636 ND 4.8 15.4 142.7 1.6 2.3 19.1 2.3 6 0.4 2.0 6 0.8
1989 118 ND 3.3 5.3 6.5 3.8 17.1 76.8 6.6 6 1.3 3.4 6 2.1
1998 95 ND 1.6 3.2 7.0 2.5 9.3 69.3 6.9 6 0.4 9.2 6 1.1
P10 1984 1,021 ND 2.8 6.8 44.8 3.0 6.5 58.0 8.8 6 2.0 2.0 6 1.0
1986 1,357 -1993 3.9 13.3 120.2 3.0 6.7 60.0 10.8 6 2.3 7.3 6 2.4
1996 9 ND 2.7 4.4 7.2 6.9 30.8 89.3 12.4 6 1.8 13.9 6 5.1
n 5 8e .600 3.1 6 0.8 8.0 6 4.0 59.1 6 45.7 2.6 6 0.5 6.8 6 2.9 60.0 6 19.9 10.7 6 4.8 4.0 6 1.8
n 5 4e 100–600 2.9 6 0.4 4.6 6 0.7 8.4 6 2.0 3.1 6 0.6 9.8 6 5.7 67.8 6 11.7 8.4 6 1.5 6.16 3.6
n 5 6e ,100 2.3 6 0.6 3.5 6 0.9 6.6 6 2.5 3.5 6 1.6 13.0 6 9.2 77.5 6 12.8 13.4 6 6.8 10.2 6 2.2
a CTL responses were determined as described previously (16, 17).
b CD4 and class I MHC expression levels were determined for cells expressing low (L), medium (M), and high (H) levels of GFP, as described in Materials and
Methods. Results were confirmed in two additional experiments.
c Average values and standard deviations for the enhancement of viral infectivity, compared to nef-deleted NL4-3 infection. Enhancement of replication in PBMC
culture is indicated for 9 to 13 days postinfection, when peak activities where observed for wild-type NL4-3 infection. Numbers show x-fold enhancement of reverse
transcriptase activity relative to nef-deleted infection. Values given for infectivity and replication were derived from three or four experiments.
d ND, not determined.
e Number of samples with a CD41 cell count .600/mm3.
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be particularly high late in infection, when the number of
uninfected CD41 target cells is greatly reduced. Under these
conditions, HIV-1 variants that show higher infectivity, or an
expanded cell and coreceptor tropism (7), might have a sub-
stantial selective advantage.
Do the observed variations in Nef cause progression to
AIDS, or are they just a phenomenon that might be unrelated
to disease? We feel that cause and effect cannot be separated
in HIV-1 infection. Clearly, the ability of HIV-1 to persist and
replicate at high levels in infected individuals is linked to pro-
gression. In a continuous evolutionary process, HIV-1 variants
that are better adapted to spread efficiently in their respective
host environment are constantly selected. New variants pre-
dominate because they have some selective advantage, either
by replicating better or by being less efficiently eliminated by
the antiviral immune response. Thus, while more aggressive
Nef variants might occur only when the immune system is
already damaged, it is obvious that these forms do emerge
because they have some advantage over the existing viral qua-
sispecies. As a consequence, HIV-1 nef alleles that are func-
tionally optimized to the host environment should lead to a
higher viral load and therefore should accelerate progression
to AIDS.
Recent studies in the SIV-macaque model demonstrated
that SIV becomes more virulent during disease progression
(22). Our results suggest that variations in Nef that evolve
during progression to AIDS might contribute to the increased
virulence of HIV-1. Late-stage HIV-1 Nef variants, which are
more active in stimulation of viral replication in T lymphocytes,
should lead to higher levels of viremia and more rapid pro-
gression to AIDS. In support of an increased virulence of late
HIV-1 isolates, it has been shown that a low maternal CD41
cell count was associated with rapid progression to AIDS in
vertically infected children (40). Additional studies with well-
characterized patient cohorts and with pathogenic Nef-SHIVs
might lead to the elucidation of the relevance of different
HIV-1 Nef properties for virulence.
In conclusion, our results suggest that the selective forces on
different Nef functions depend on the clinical stage of HIV-1
disease. The adaptive evolution of HIV to its host environment
results in particularly high activity in Nef functions that pro-
mote the escape of HIV-1 from immune surveillance during
the asymptomatic stage. In comparison, the in vivo selective
forces drive Nef properties that enhance viral spread in a more
direct manner after progression to AIDS. Importantly, our
findings provide strong evidence that these independent in
vitro Nef functions all contribute to viral spread in vivo. There-
fore, pharmaceutical agents should disrupt molecular interac-
tions of Nef that are critical for all these in vitro functions, e.g.,
membrane association. Finally, our results suggest that HIV-1
nef variants with increased pathogenicity emerge in a signifi-
cant number of infected individuals and contribute to the pro-
gression to AIDS.
FIG. 5. Functional activity of primary nef alleles obtained at different stages of infection. The x-axis gives the number of CD41 cells per
microliter at the time of PBMC sampling. A total of 20 samples derived from eight patients (SP7, SP8, P2, P5, P7, P8, P9, and P10 (Tables 1 and
2) were analyzed. Average values (n ) for downregulation of CD4 (at medium GFP expression levels) and class I MHC (at high GFP expression
levels), as well as enhancement of HIV-1 replication and infectivity, are indicated. Values were determined as described in Materials and Methods
and in Table 2.
FIG. 6. Schematic model for the modulation of independent Nef
functions during the course of HIV-1 infection. The black bars indicate
the changes in Nef function observed during progression to AIDS. In
immunocompetent hosts, Nef efficiently downmodulates class I MHC
to prevent CTL lysis of infected cells. After the breakdown of the
immune system, the selective forces drive variations in Nef that are
associated with an increased activity in the stimulation of HIV-1 rep-
lication and reduced functional activity in class I MHC downregula-
tion. The ability of Nef to downregulate CD4 and to enhance virion
infectivity is enhanced in some AIDS patients and is likely to optimize
viral spread in a host environment where uninfected CD41 target cells
become limited. The acute phase of infection has not been investigated
in this study. Symbols: 2, downmodulation; 1, enhancement.
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